FIRST-IN-CLASS SEMAPHORIN 3A SMALL-MOLECULE INHIBITOR FOR THE TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA

$199,897FY2020Defense Health AgencyDOD

Regenerate Therapeutics Inc

Investigators